Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

20250 citationsJournal Articlehybrid Open Access

Authors

Esther Sanfeliu · Breast Cancer Research Foundation

Anabel Martínez-Romero · Breast Cancer Research Foundation

Mercedes Marín‐Aguilera · Genomics Medicine (Ireland)

Sandra Cobo · Breast Cancer Research Foundation

Blanca González‐Farré · Breast Cancer Research Foundation

Eva Hernández‐Illán · Hospital Clínic de Barcelona

Pedro Jares

Abstract

HER2DX reflects key biological and pathologic features of HER2+ breast cancer and independently predicts pCR, supporting its utility for individualized treatment decision-making.

Topics & Keywords

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies PARP inhibition in cancer therapy

Publication Details

Published in: Clinical Cancer Research

Volume 32, Issue 3, pp. 570-580

DOI: 10.1158/1078-0432.ccr-25-3123

Field-Weighted Citation Impact: 0.00

Command Palette

Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

Authors

Abstract

Topics & Keywords

Publication Details